This year’s Multi-Functional Cell Therapies Summit is the important venue for companies presenting crucial aspects on the development of cell based therapies. Nextera’s CEO, Geir Åge Løset will give the presentation ” Combinatorial specificity profiling and engineering to safeguard and optimize TCR reactivity” on May 5th. He will show how the employment of the NextCore HLA platform can foster the development of safer and better T cell therapies. Nextera will have a virtual booth for information and partnering provided by CBO Ole Henrik Brekke and Group Lead, Discovery Gøril Berntzen.
Nextera partnering Multi-Functional Cell Therapies Summit, May 4-6
